hero section gradient
15 handpicked stocks

Bio-Hacking Portfolio

Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Summary and investor key takeaways for the provided Bio-Hacking Portfolio market capitalisation breakdown.

Key Takeaways for Investors:
  • Large-cap dominance generally means lower volatility and closer tracking to broad market performance, reducing idiosyncratic risk.
  • Treat this basket as a core holding offering diversified exposure, not a short-term speculative trade.
  • Expect steadier, long-term appreciation rather than rapid, explosive gains; growth is likely moderate and gradual.
Total Market Cap
  • ZEPP: $721.83M

  • MOVE: $5.96M

  • WLDS: $16.04M

  • Other

About This Group of Stocks

1

Our Expert Thinking

This portfolio targets the growing intersection of technology and biology. As consumers increasingly seek personalized, data-driven approaches to optimize health and performance, these companies are positioned to benefit from the shift toward proactive wellness management and human enhancement.

2

What You Need to Know

These stocks span multiple sectors including biotechnology, wearable tech, nutritional supplements, and health analytics. They represent a high-growth niche market driven by consumers willing to invest in optimization of their physical and cognitive capabilities through cutting-edge products and services.

3

Why These Stocks

Each company was selected for its innovative approach to human enhancement, from advanced wearable sensors that track biometrics to genetic-level therapeutics. With strong intellectual property and clear commercialization paths, these firms are leading pioneers in the rapidly expanding bio-hacking movement.

Why You'll Want to Watch These Stocks

🧬

The Health Revolution You Can't Ignore

Bio-hacking is transforming from niche hobby to mainstream practice as consumers increasingly take control of their health data. These companies are leading the charge toward personalized wellness.

📊

Data-Driven Growth Potential

With AI advancements accelerating product development and expanding market reach, these companies sit at the convergence of two powerful trends: personal health optimization and big data analytics.

🔮

Early Access to the Future of Wellness

Investing in bio-hacking means positioning yourself at the forefront of human enhancement technology before it becomes commonplace. These stocks represent tomorrow's approach to health today.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions